Acunova Life Sciences Limited Abbreviated Accounts 31 March 2013

VEDNESDAY



A23 21/08/2013 COMPANIES HOUSE

Acunova Life Sciences Limited Independent auditors' Report

Independent auditors' report to Acunova Life Sciences Limited under section 449 of the Companies Act 2006

We have examined the abbreviated accounts which comprise the Abbreviated Balance Sheet and the related notes, together with the full accounts of the company for the year ended 31 March 2013 prepared under section 396 of the Companies Act 2006

Respective responsibilities of directors and auditors

The directors are responsible for preparing the abbreviated accounts in accordance with section 444 of the Companies Act 2006. It is our responsibility to form an independent opinion as to whether the company is entitled to deliver abbreviated accounts to the Registrar of Companies and whether the abbreviated accounts have been properly prepared in accordance with the regulations made under that section and to report our opinion to you

We conducted our work in accordance with Bulletin 2008/4 issued by the Auditing Practices Board In accordance with that Bulletin we have carried out the procedures we considered necessary to confirm, by reference to the full accounts, that the company is entitled to deliver abbreviated accounts and that the abbreviated accounts are properly prepared

Opinion

In our opinion the company is entitled to deliver abbreviated accounts prepared in accordance with section 444(3) of the Companies Act 2006, and the abbreviated accounts have been properly prepared in accordance with the regulations made under that section

(Senior Statutory Auditor)

for and on behalf of Taparia Consultants Limited Accountants and Statutory Auditors

6 August 2013

1096 Uxbridge Road Hayes

Middlesex

UB4 8QH

Acunova Life Sciences Limited

Registered number:

5605926

Abbreviated Balance Sheet

as at 31 March 2013

| t | Notes | 2013 | | 2012 |
|--------------------------------|----------|---------|----------|-----------|
| | | € | | € |
| Current assets | | | | |
| Debtors | 199,343 | | 41,548 | |
| Cash at bank and in hand | 75,543 | | 4,135 | |
| | 274,886 | | 45,683 | |
| Creditors: amounts falling due | | | | |
| within one year | (75,092) | l | (33,674) | |
| Net current assets | | 199,794 | , | 12,009 |
| Net assets | | 199,794 | - | 12,009 |
| Capital and reserves | | | | |
| Called up share capital | 2 | 114,000 | | 114,000 |
| Profit and loss account | | 85,794 | | (101,991) |
| Shareholders' funds | | 199,794 | _ | 12,009 |

The accounts have been prepared in accordance with the provisions in Part 15 of the Companies Act 2006 applicable to companies subject to the small companies regime

Kohkan Shamshi

Director

Approved by the board on 6 August 2013

Acunova Life Sciences Limited Notes to the Abbreviated Accounts for the year ended 31 March 2013

1 Accounting policies

Basis of preparation

The accounts have been prepared under the historical cost convention and in accordance with the Financial Reporting Standard for Smaller Entities (effective April 2008)

Turnover

Turnover represents the value, net of value added tax and discounts, of work carried out in respect of services provided to customers. The company recognises revenue in the period in

Reporting currency

As the company's day to day trading operations are conducted in Euros, the directors are of the opinion that the company's functional currency is Euros and therefore the appropriate reporting currency

Foreign currencies

Transactions in foreign currencies are recorded at the rate ruling at the date of the transaction Monetary assets and liabilities denominated in foreign currencies are translated at the rate of exchange ruling at the balance sheet date. All differences are taken to the profit and loss account

Pensions

The company operates a defined contribution pension scheme. Contributions are charged to the profit and loss account as they become payable in accordance with the rules of the scheme.

Comparatives

The previous years accounts were stated in pound sterling and have now been translated in Euros. The previous years accounts were unauditied.

| 2 | Share capital | Nominal value | 2013 Number | 2013 € | 2012 € |
|---|------------------------------------|---------------|----------------|-----------|-----------|
| | Allotted, called up and fully paid | | | | |
| | Ordinary shares | £1 each | 95,000 | 114,000 | 114,000 |

3 Related parties

The company's immediate holding company is Manipal Acunova Ltd, which owns 100% of Acunova Life Sciences Ltd issued share capital

During the year the company traded with one other group company, Ecron Acunova GmbH a company incorporated in Germany The balance due from them at the year end was as follows

Ecron Acunova GmbH (Advance against invoices) 115,436

Amounts of €55,233 and €18,342 shown in Trade Debtors and Trade Creditors respectively were taken over by Ecron Acunova GmbH on transfer of contracts to them on 1 May 2013